Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585098 | 0.84 | AR (0.52) | ARTSHRUPP1 | |
| SCHEMBL6895215 | 0.84 | AR (0.37) | ARESR1ESR2TSHRUPP1 | |
| SCHEMBL10742861 | 0.80 | AR (0.40) | ARESR1ESR2TSHRUPP1 | |
| SCHEMBL1930255 | 0.80 | AR (0.53) | ARPGR | |
| SCHEMBL998935 | 0.80 | AR (0.38) | ARESR1ESR2TSHRUPP1 | |
| SCHEMBL29451048 | 0.79 | TRPA1 (0.50) | ARESR1ESR2TSHRTRPA1 | |
| SCHEMBL2137032 | 0.79 | TRPA1 (0.50) | ARESR1ESR2TSHRTRPA1 | |
| SCHEMBL13981332 | 0.76 | TRPA1 (0.36) | ARESR1ESR2TRPA1ATM | |
| SCHEMBL21425352 | 0.76 | ESR1 (0.44) | ARESR1ESR2TSHRSNCA | |
| SCHEMBL17442944 | 0.76 | AR (0.35) | ARESR1ESR2TSHRUPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| EP-3765446-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.p.A. (IT) | 2021-01-20 | — | — | EP | disclosed |
| CN-111868035-A | Substituted pyrazole FFA4/GPR120 receptor agonists | 阿克萨姆股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019175152-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.P.A. (IT) | 2019-09-19 | — | — | WO | disclosed |
| CN-103373965-B | The preparation method of etravirine and intermediate thereof | SHANGHAI DESANO PHARMACEUTICAL CO.,LTD. (CN) | 2016-04-27 | — | — | CN | disclosed |
| CN-102675220-B | Etravirine preparing method and intermediate of etravirine | PHARMABLOCK NANJING R & D CO LTD | 2014-03-19 | — | — | CN | disclosed |
| CN-103373965-A | Preparation methods of etravirine and intermediate body thereof | SHANGHAI DESANO PHARMACEUTICAL CO LTD | 2013-10-30 | — | — | CN | disclosed |
| CN-101553483-B | 2-(piperidin-4-yl)-4-phenoxy-or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE | 2013-04-17 | — | — | CN | disclosed |
| CN-102675220-A | Etravirine preparing method and intermediate of etravirine | NANJING REMEDIES DRUG RES & DEV CO LTD | 2012-09-19 | — | — | CN | disclosed |
| CN-1934071-A | Carboxamide derivatives useful as adrenergic receptors | PFIZER LTD (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1910143-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5643929-A | TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES | SANOFI WINTHROP, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5464848-A | 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0413289-A2 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | AR 610/4885ESR1 1331/4885ESR2 679/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | AR 610/4885ESR1 1331/4885ESR2 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.